TEMD-2 Polypharmacy Study: Factors in Type 2 Diabetes Patients, Türkiye 2023

A nationwide cross-sectional study of 4,956 patients with Type 2 Diabetes Mellitus (T2DM) in Türkiye, conducted in 2023. The dataset, authored by Fatma Tuğçe Şah Ünal, analyzes polypharmacy prevalence and associated demographic, comorbidity, and complication factors. Polypharmacy was defined as the use of five or more medications and was observed in 46.7% of the patient cohort.

Use Cases

• Predicting polypharmacy risk based on patient age, diabetes duration, and comorbidity profiles mentioned in the description
• Analyzing associations between specific complications (e.g., neuropathy, nephropathy) and medication burden
• Modeling the relationship between polypharmacy and adverse outcomes like severe hypoglycemia
• Identifying demographic and clinical subgroups at highest risk for complex pharmacological regimens

Strengths

• Nationwide scale with 4,956 patient records from a 2023 survey
• Clear definition of polypharmacy (≥5 medications) and detailed statistical results reported
• Includes analysis of multiple independent predictors such as age, diabetes duration, and specific comorbidities

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data reflects a single-country (Türkiye) and single-year (2023) context, which may limit generalizability

Provenance

Source

figshare

Collection Method

Nationwide cross-sectional survey

Time Range

2023

Freshness

Last updated 2026-05-14 06:18:29; freshness should be verified

Geography

Türkiye